Research

Applied research in neuromuscular diseases

Search Projects

Projects

  • Role of CMG2 and its associated effectors as potential therapeutic targets and in the pathophysiology of congenital muscular dystrophies due to collagen VI deficiency

    Leader
    Cecilia Jiménez Mallebrera
    Code
    PCP00387
    Starting date
    2023
    End date
    2026
    Funded by
    Alexion Pharmaceuticals Inc.

  • Cerrando la brecha terapeutica para Distrofias Musculares Congenitas. Estrategias para mejorar la eficacia, liberacion y seguridad de terapias basadas en CRISPR/Cas9 y oligonucleotidos

    Leader
    Cecilia Jiménez Mallebrera
    Announcement
    Conveni
    Code
    PFNR0182
    Starting date
    2023
    End date
    2025
    Funded by
    Fundación Noelia. Niños Contra la Distrofia Muscular Congénita por Déficit de Colágeno VI

  • Cerrando la brecha terapeutica para Distrofias Musculares Congenitas. Estrategias para mejorar la eficacia, liberacion y seguridad de terapias basadas en CRISPR/Cas9 y oligonucleotidos

    Leader
    Cecilia Jiménez Mallebrera
    Announcement
    Proyectos de Investigación
    Code
    PI22/01382
    Starting date
    2023
    End date
    2025
    Funded by
    Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD, Jiménez Mallebrera, Cecilia

  • DYSTRO-SMARTY: La plataforma de Nanomedicina para terapias avanzadas contra lasvDistrofias Musculares Congénitas.

    Leader
    Cecilia Jiménez Mallebrera
    Announcement
    Conveni
    Code
    PCP00358
    Starting date
    2023
    End date
    2024
    Funded by
    Fundación Salud 2000 (Merck Salud)

  • Cohort of Spanish Patients with Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)

    Leader
    Carlos Ignacio Ortez Gonzalez
    Announcement
    Conveni
    Code
    PCP00337
    Starting date
    2022
    End date
    2024
    Funded by
    PTC Therapeutics International Limited

  • DYSTRO-SMARTY: A novel nanotechnology platform for delivery of nucleic acids to treat Collagen VI-related Congenital Muscular Dystrophy

    Leader
    Cecilia Jiménez Mallebrera
    Code
    PFNR0160
    Starting date
    2022
    End date
    2023
    Funded by
    Fundación Noelia. Niños Contra la Distrofia Muscular Congénita por Déficit de Colágeno VI

  • Movilidad de profesionales sanitarios e investigadores del SNS (M-BAE)

    Leader
    Cecilia Jiménez Mallebrera
    Announcement
    M-BAE
    Code
    BA21/00010
    Starting date
    2022
    End date
    2022
    Funded by
    Instituto de Salud Carlos III (ISCIII)

  • Spinal muscular atrophy disease registry

    Leader
    Andrés Nascimento Osorio
    Announcement
    Convenio
    Code
    PCP00323
    Starting date
    2021
    End date
    2026
    Funded by
    Novartis Farmacéutica, S.A

  • ArmTracker: A state-of-the-art wearable system to assess upper limb motor function in reallife conditions for patients with Duchenne muscular dystrophy and spinal muscular atrophy.

    Leader
    Daniel Natera de Benito
    Announcement
    Projectes de recerca en malalties minoritàries
    Code
    561/C/2020
    Starting date
    2021
    End date
    2024
    Funded by
    Fundació La Marató de TV3

  • Emerging biomarkers for spinal muscular atrophy

    Leader
    Cecilia Jiménez Mallebrera
    Announcement
    Biogen
    Code
    ES-SPN-1188
    Starting date
    2021
    End date
    2023
    Funded by
    Biogen International GmbH